Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESERVE-003
2023-505311-20-00Phase 3Withdrawn
- Sponsor
- OncoC4
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 3, randomised trial of gotistobart in non-small cell lung cancer (NSCLC) (2 arms), sponsored by OncoC4. Primary endpoint: Overall survival. Planned start Dec 2023; status: withdrawn.
02
Drugs
gotistobart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-505311-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505311-20-00.